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Transgenic chemokine-secreting parasites were generated and used to actively 
recruit immune cells into Leishmania lesions.  It was hypothesized that the chemokine 
induced cell migration would influence the magnitude and character of the immune 
response and thereby effect the outcome of disease.  Two different transgenic chemokine-
secreting parasites were engineered.  One transgenic parasite secretes murine MCP-1, a 
CC chemokine primarily responsible for macrophage recruitment.  The other transgenic 
parasite secretes murine IP-10, a CXC chemokine known to attract activated T-cells.  
Both transgenic parasites transcribed murine chemokine mRNA, translated murine 
chemokine protein, and infected and replicated inside resting peritoneal macrophages 
similar to wild-type parasites.  However, the two transgenic parasites caused diverse 
phenotypes in infected mice.  The MCP-1 secreting parasites caused little or no 
detectable lesions, while the IP-10 secreting parasites caused lesions that were 
significantly larger than the wild-type infected mice.  The healing phenotype caused by 
MCP-1 secreting parasites was further analyzed.  
  
Infection of BALB/c, C57BL/6, or MCP-1 knockout (KO) mice with MCP-1 
secreting parasites resulted in minimal lesion development compared to mice infected 
with wild-type parasites.  MCP-1 secreting parasites caused substantial lesions with 
relatively high numbers of parasites in CCR2 KO mice indicating that the parasites are 
viable and healthy, and that the lack of lesion development is CCR2- dependent.  The 
enumeration of transgenic MCP-1 parasites in lesions demonstrated a significant 
reduction in parasite numbers, which coincided with an increase in CCR2-positive 
macrophage migration on day 7.  CCR2-positive macrophages isolated from ears of mice 
infected with transgenic MCP-1 parasites contained virtually no parasites, whereas 
infection with wild-type parasites resulted in heavily-infected macrophages in lesions.  
The lack of parasite survival in mice infected with MCP-1 secreting parasites suggests 
that parasite-derived MCP-1 is recruiting a population of CCR2-positive macrophages to 
the lesion that efficiently kill Leishmania parasites.  In-vitro studies revealed that optimal 
parasite killing required the recruitment of CCR2-positive macrophages followed by 
stimulation with a combination of both MCP-1 and IFN-γ.  This work suggests that the 
parasite-derived MCP-1 can recruit a restrictive population of CCR2-positive 
macrophages into lesions that can be optimally stimulated by MCP-1 and IFN-γ to 
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CHAPTER 1: INTRODUCTION 
Innate Immunity 
Overview 
 The immune system is composed of two branches innate and adaptive immunity.  
Innate immunity occurred evolutionarily prior to adaptive immunity.  Thus, some form of 
innate immunity exists in all multi-cellular organisms1.   
Both the innate and adaptive components contain different cells, functions, and 
roles.  Cells that make up the innate component of the immune system include 
neutrophils, macrophages, natural killer (NK) cells, and dendritic cells (DCs).  One major 
difference between innate and adaptive immunity is the receptors and mechanisms that 
are used to recognize foreign antigens.  Innate immune cells have germ-line encoded 
receptors, meaning that the specificity toward particular microbial products is pre-
determined and evolved through natural selection.  Innate immune cells are not able to 
recognize every particular antigen to which the host is exposed, but merely focus on 
highly conserved antigens from large classes of microorganisms.  These highly conserved 
structures are known as pathogen-associated molecular patterns (PAMPs) and they are 
recognized by pattern recognition receptors (PRRs) located on the surface of innate 
immune cells2.  Examples of PAMPs include bacterial lipopolysaccharide, peptidoglycan, 
lipotechoic acid, bacterial DNA, and double-stranded RNA.  PAMPs share several 
common features including that they are usually produced by microbial pathogens, but 
not the host.  Second, the PAMPs are usually vital for the microbial pathogen’s survival 
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or pathogenicity.  Third, these structures are usually shared by large classes of microbial 
pathogens3.   
The PRRs that recognize the PAMPs can be divided into three groups based on 
function: secreted, endocytic, and signaling.  Secreted PRRs opsonize foreign pathogens 
to be recognized by the complement system or taken up by phagocytes.  An example 
includes mannan-binding lectin, which can bind to microbes leading to the activation of 
the lectin dependent complement pathway.  Endocytic pattern recognition receptors are 
found on the surface of innate immune cells.  These receptors bind and take up microbes 
for them to be broken down inside the phagolysosome and packaged into MHC II 
receptors for presentation to T-cells.  Two examples include the mannose receptor and 
scavenger receptors.  Signaling receptors are PRRs that bind highly conserved microbial 
patterns to induce cell signaling.  The cell signaling leads to the expression of immune-
response genes such as inflammatory cytokines and the upregulation of co-stimulatory 
molecules3 (Figure 1).  An example is Toll-like receptors such as (TLR)4 and TLR2. 
Monocytes 
Mononuclear phagocytes are a diverse group of cells that express a wide range of 
phenotypes4.  Recently, two murine monocyte subsets have been identified.  These 
subsets include inflammatory and resident monocyte subsets.  These subsets were 
identified from experiments involving knock-in mice expressing GFP in place of one 
allele of the chemokine receptor CX3CR15.  Analysis of subsets that were green 
fluorescent protein (GFP)-positive compared to those that were GFP-negative revealed 














Figure 1.  Recognition of microbial product by toll-like receptors activates 
adaptive immunity.  Toll-like receptor ligands such as LPS and CpG DNA 
activate APCs to produce the pro-inflammatory cytokine IL-12 and upregulate 
co-stimulatory molecules, which help to activate adaptive immunity.  From 












macrophages (CX3CR1+, CCR2-, Gr-1-) compared to those that migrate into sites of 
inflammation (CX3CR1-, CCR2+, Gr-1+).  The Gr-1+ monocytes express the chemokine 
receptor CCR2 and respond to MCP-1. 
 Recently, CD68+Gr-1+ restrictive macrophages have been identified6 that are 
capable of controlling T. gondi infection.  The CCR2+ Gr-1+ monocytes are believed to 
become CD68+Gr-1+ restrictive macrophages.  During T. gondi infection, MCP-1 is 
produced and is believed to recruit the inflammatory CCR2+Gr-1+ monocytes from the 
bloodstream and into the site of infection.  The inflammatory monocytes become 
CD68+Gr-1+ restrictive macrophages and control the parasite infection7.  
Macrophages 
 Macrophages are a heterogenous population of cells with diverse physiologies and 
distinct immunological functions.  One of the first macrophage populations identified is 
known as the classically activated macrophage.  Classically activated macrophages 
require two signals to become fully activated.  They require IFN-γ to prime the 
macrophages, however, IFN-γ alone will not activate the macrophages8.  These cells also 
require a second signal: TNFα or an inducer of TNFα.  This usually comes in the form of 
a TLR agonist, such as LPS, lipotechoic acid, bacterial flagellin, or any microbial product 
that will ligate a TLR and induce TNFα.  Macrophages that receive both signals will 
produce toxic oxygen radicals (RO) and stimulate the inducible NO synthase (iNOS) 
gene to produce nitric oxide (NO)9.  The RO and NO enhance the ability of classically 
activated macrophages to kill intracellular microorganisms.   However, NO production 
will not occur, nor will the macrophages be classically activated to kill intracellular 
microorganisms, by merely treating the cells with IFN-γ.  In addition, classically 
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activated macrophages secrete the pro-inflammatory cytokines TNFα, IL-12, IL-1, and 
IL-6 and also upregulate MHC II molecules and co-stimulatory molecules such as 
CD8610. 
 Two other types of activated macrophages have been identified: alternatively 
activated and type II-activated macrophages.  Alternatively activated macrophages are 
macrophages that, when treated with IL-4, become activated in a manner different than 
classically activated macrophages.  These cells when activated secrete IL-10 and IL-1R 
antagonist.  In addition, they do not produce NO10, but instead induce arginase11, which 
affects their ability to kill intracellular microorganisms.  These cells are poor antigen 
presenting cells and are believed to play a role in wound repair and angiogenesis.  Type 
II-activated macrophages require two signals like classically activated macrophages.  
Type II-activated macrophages require a stimulatory signal such as LPS that by itself 
would lead to high amounts of IL-12 production.  In addition to the stimulatory signal, 
the type II-activated macrophages require Fcγ receptor (FcγR) ligation to suppress IL-12 
production and enhance production of IL-1010.  Immune complexes, which are any 
antigen-antibody complex, ligate the Fcγ receptor. 
Chemotaxis & Chemokines 
 Chemotaxis is the directed migration of leukocytes toward a chemoattractant 
gradient.  Cells in the immune system use chemotaxis to migrate toward injury or 
infection.  The first step in this directed migration is the exiting of leukocytes from the 
blood into tissue.  This process is called diapedesis.  There are several distinct steps taken 
by a leukocyte to undergo diapedesis and leave the bloodstream toward a chemoattractant 
gradient located in the tissue.  First, the leukocyte loosely adheres to the vascular 
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endothelium via a family of cell-surface adhesion molecules called selectins.  Selectin-
mediated adhesion is of low affinity.  Therefore, in the presence of the shear force 
provided by the flow of blood, selectin-mediated adhesion causes the leukocyte to appear 
to roll on the endothelium.  Second, the leukocyte adheres firmly to the endothelium via 
integrins.  Integrins are heterodimeric cell surface receptors, which mediate firm adhesion 
and allow leukocytes to move out of the blood vessel into tissue through small openings 
called fenestrations1 (Figure 2).   
The classic chemoattractants include bacterial N-formylated peptides (f-Met-Leu-
Phe), complement anaphylotoxins C3a and C5a, and lipid molecules such as leukotriene 
B4, and platelet-activating factor.  Another category of chemoattractants are the 
chemotactic cytokines known as chemokines.  Chemokines are basic proteins with 
molecular masses ranging 6 to 14 kilodaltons (kDa) and chemoattractant properties12.  
Most often chemokines are believed to act as monomers13.  Most chemokines have at 
least four cysteines with two disulfide bonds.  One disulfide bond is located between the 
first and the third and the other is located between the second and fourth cysteine.  These 
bonds result in an overall structure that involves three β-sheets with short loops in a 
Greek key formation12.  Chemokines are divided into four families based on the location 
of the two cysteines present in N-terminal portion of the chemokine protein sequence.  
The four families include the CC, CXC, C, and CX3C chemokines.  Both classic 
chemoattractants and chemokines signal through seven-transmembrane-spanning G-
protein coupled receptors (GPCR) (Figure 3).  The chemokine receptors include: 
CXCR1-5, and CCR1-9, CR1, and CX3CR114. 








Figure 2.  Chemotaxis.  Leukocytes go through a series of steps to migrate from the bloodstream toward 
a chemoattractant located in the tissue.  These steps include rolling mediated by selectins, tight binding 

















Figure 3.  G-protein coupled receptor (GPCR).  GPCRs 
contain seven transmembrane spanning regions with the N-
terminal segment facing the outside of the plasma 
membrane and the C-terminal segment facing the 
cytoplasmic side.  Ligand binding to GPCRs activates a 












Chemokines are major contributors to both innate and adaptive immunity.  They 
are important for innate immunity to attract monocytes, immature DCs, and NK cells to 
sites of infection as the first line of defense.  In addition, chemokines are required in 
adaptive immunity for lymphocyte development and function by guiding the migration of 
various types of lymphocytes: immature, mature/naïve, effector, and memory15.  For 
example, several chemokines control the migration of lymphocytes within primary 
lymphoid organs16.  Finally, chemokines play an important role in bridging innate and 
adaptive immunity by bringing T-cells, B-cells, and DCs together in the secondary 
lymphoid organs for activation purposes17. 
IP-10 
 Interferon-γ inducible protein, also known as IP-10 or CXCL10, is a CXC 
chemokine known to attract NK cells, CD8+ T-cells, and both CD4+ T-cell subsets18, but 
not neutrophils19.  Structurally, IP-10 exists as three different crystal forms; monomer, 
dimer, and tetramer.20  IP-10 binds to and activates the chemokine receptor, CXCR3.  IP-
10 has long been considered a Th1 chemokine, and it can recruit Th1 cells and bias the 
immune response toward a Th1 response21.  This could create a healing phenotype in 
mice infected with L. major IP-10.  However, recently there has been major focus on 
CD4+ CD25+ T-regulatory cells (Treg) that express CXCR322.  T-regulatory cells have 
been shown to suppress the immune response against Leishmania through both IL-10 
dependent and independent mechanisms, which leads to parasite survival23.  Therefore, L. 




 Monocyte chemotactic protein, also known as CCL2, is a CC chemokine known 
to attract monocytes, NK cells, both CD4+ T-cell subsets, eosinophils, basophils, and 
DCs, but not neutrophils24.  Structurally, MCP-1 can exist in several crystal forms 
including as a monomer, dimer, and tetramer25, although it is uncertain at this time which 
crystal form activates the MCP-1 receptor, CCR226.  CCR2 exists in two forms: CCR2A 
and CCR2B.  Both forms have identical 5’ untranslated and transmembrane regions, but 
differ in their carboxyl terminus27.  Post-translational modification of MCP-1 has been 
shown to affect its biochemical and biological activities28;29.  MCP-1 is believed to 
influence T-helper cell development.  In some cases, MCP-1 has been shown by others to 
stimulate Th2 polarization making MCP-1 KO mice more resistant to intracellular 
parasite infection involving Leishmania30.  However, CCR2, the receptor for MCP-1, has 
been shown to stimulate Th1 polarization making CCR2 KO mice susceptible to 
intracellular parasite infection involving Leishmania31.  There are several explanations 
for the differences in T-cell polarization.  First, CCR2 has high affinity ligands (MCP-1 – 
MCP-5) in mice and four in humans, and these could possibly exert different biological 
effects on CCR2.  Secondly, there could be a receptor for MCP-1 that has yet to be 
discovered.  MCP-1 binding to this unknown receptor could promote Th2 biasing, 
whereas binding to CCR2 could drive a Th1 response.  Activation of this unknown 
receptor would override the CCR2 activation when both receptors are present26.  MCP-1 
has received the majority of its attention from its ability to recruit monocytes.  For 
example, MCP-1 expression occurs in a variety of disease states that involve monocyte 
infiltration such as atherosclerosis and multiple sclerosis26.   A transgenic mouse was 
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developed that overexpresses MCP-1.  These mice express very high levels of MCP-1 in 
multiple organs and serum, and showed no evidence of monocyte infiltration.  These 
mice were more susceptible to infection with the intracellular pathogens Listeria 
monocytogenes and Mycobacterium tuberculosis,32 and this susceptibility is believed to 
be a result of the high levels of MCP-1 that desensitized the CCR2 receptor, thus, 
preventing monocyte infiltration into the sites of infection. 
Adaptive Immunity 
Overview 
 Innate immunity can not always completely eliminate certain microorganisms.  
Therefore, the adaptive component of the immune system has evolved to provide a more 
versatile line of defense against infectious pathogens.  The cells that make up adaptive 
immunity are known as lymphocytes.  There are two types of lymphocytes, B-cells and 
T-cells, that have completely different functions and eliminate different types of 
microorganisms. 
 There are several properties that distinguish adaptive immunity from innate 
immunity.  These properties include specificity, diversity, regulation, memory, and non-
reactivity to self.  Specificity refers to an immune response to one particular antigen.  
Lymphocytes possess rearranged receptors that will specifically bind one particular 
antigen.  When the lymphocyte receptor encounters its antigen than the receptor binds the 
antigen, leading to cell proliferation.  This will result in the establishment of a 
lymphocyte clone with the specificity for a single antigen.  Diversity refers to the vast 
repertoire of receptor possibilities that the lymphocytes can possess.  By recombining 
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their receptors, lymphocytes have the capacity to recognize 109 – 1011 antigen specific 
epitopes.  Regulation refers to the adaptive immune response returning to homeostasis 
after the host encounters a foreign entity and adaptive immunity eliminates this entity.  
Memory refers to the established protection that a host develops after adaptive immunity 
responds and eliminates an infectious pathogen.  Non-reactivity to self refers to the fact 
that lymphocytes are part of adaptive immunity and do not recognize self-antigens so as 
to prevent attacking the host.  Auto-immunity occurs in those cases where lymphocytes 
recognize self-antigens33. 
 The adaptive immune response may be divided into three phases—the recognition 
of antigen, activation of lymphocyte, and effector phases.  Each lymphocyte has a 
receptor specific for an individual antigen.  During the recognition phase, the lymphocyte 
locates and binds to a specific antigen that it recognizes and thus the lymphocyte 
undergoes clonal expansion.  Clonal expansion results in lymphocyte proliferation so that 
there is a large lymphocyte clone with receptors of the same specificity.  After the 
lymphocyte recognizes its particular antigen, the activation phase begins.  Activation 
requires two distinct signals.  The first signal is the antigen and the second signal is either 
a microbial product or component of the innate immune response.  This is the two-signal 
hypothesis for lymphocyte activation, which ensures that the adaptive immune response 
is specific and also necessary.  The activation phase involves the synthesis of new 
proteins, cell proliferation, differentiation into effector cells, or differentiation into 




 There are two types of adaptive immune responses—humoral immunity and cell-
mediated immunity.  These immune responses differ by the cells involved and by the 
different types of microorganisms that each immune response responds.  Humoral 
immunity involves B-lymphocytes and antibody production and is necessary for 
defending against extracellular toxins and extracellular pathogens such as extracellular 
bacteria and worms.  Cell-mediated immunity involves T-lymphocytes and is required for 
eliminating intracellular pathogens. 
T-cells 
 T-lymphocytes originate in the bone marrow, but migrate to the thymus for 
maturation.  It is during the maturation period that the T-cell receptor (TCR) on T-cells 
undergoes gene rearrangement, positive selection, and negative selection.  During 
positive selection, T-lymphocyte precursors with antigen receptors that bind some self-
ligand with low affinity are selected to survive34.  During negative selection, T-
lymphocytes whose antigen receptors bind self-antigen with high affinity are selected for 
cell death35.  The TCR consists of two polypeptides called TCRα and TCRβ chains 
linked by a disulfide bond.  This receptor allows the T-cells to have a single specificity 
for one particular antigen.  The TCR is able to recognize antigens when they are 
degraded, processed, and presented in MHC molecules present on the surface of 
professional antigen presenting cells (APCs)36.  APCs include dendritic cells (DCs), 
macrophages, and B-cells.  The APCs present antigens to T-cells using MHC receptor 
molecules.  Exogenous antigens taken up by APCs are degraded in the phagolysosome 
before being packaged into MHC II molecules to be presented to T-cells.  Endogenous 
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antigens are packaged into MHC I molecules in the endoplasmic reticulum (ER) and the 
MHC I molecules are sent to the cell surface for presentation to T-cells. 
 There are two types of T-cells that are divided based on surface markers and 
effector functions.  The two T-cell types can also be distinguished based on the cell 
surface proteins—CD4 or CD8.  CD4+ and CD8+ T-cells differ in the class of MHC 
molecule that they recognize.  CD4 binds to the MHC II molecule and CD8 binds to 
MHC I molecules.  CD8+ cytotoxic T-cells (CTLs) are specialized to kill any cell that 
expresses an MHC I molecule with their peptide loaded inside of it.  The main function 
of the CD4+ T-cells is to recognize their particular peptide in MHC II molecules on the 
surface of APCs and activate these cells.  For example, CD4+ T-cells recognize peptides 
bound to MHC II molecules on B-cells and then stimulate the B-cells to produce 
antibody.  CD4+ T-cells can also recognize peptides bound to MHC II molecules on 
macrophages and activate the macrophages to destroy intracellular pathogens present 
inside the macrophage.  CD4+ T-cells can differentiate into two different T-cell subsets, 
Th1 and Th2 cells depending on the cytokine environment.  Th1 cells produce 
proinflammatory cytokines such as IFN-γ and TNFα, which are required for macrophage 
activation and intracellular killing in cell-mediated immunity.  Th2 cells produce anti-
inflammatory cytokines such as IL-4, IL-5, and IL-13 and are required for B-cell 
activation and antibody production in humoral responses33.  
CD4+ regulatory T-cells (Treg) 
The immune system has established a system of checks and balances to be able to 
both protect against infectious agents and maintain tolerance to autoantigens.  Therefore, 
a network of CD4+ regulatory T-cells (Treg) is present to maintain the balance between 
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these two very different immunological outcomes.  CD4+ Treg cells can be divided into 
two categories: induced (iTreg) and naturally occurring (nTreg).  iTreg cells produce 
certain signature cytokines as a result of localized environment and these signature 
cytokines serve as the main suppressive activity.  Examples of iTregs include IFN-γ 
producing Th1 cells, IL-4 producing Th2 cells, IL-10 producing Tr1 cells, and TGF-β 
secreting Th3 cells.  nTregs develop normally through T-cell maturation in the thymus 
and represent 1-10% of the total CD4+ T-cells.  nTregs constitutively express CD25 and 
Forkhead transcription factor (FOXP3)37.  These cells play a major role preventing self-
reactivity and help to establish tolerance when necessary.  Recently, nTregs have been 
shown to express the chemokine receptor CXCR3, the receptor for the CXC chemokine, 
IP-1022. 
Cell-mediated Immunity & Macrophage Activation 
 Many microorganisms live inside host cells where it is impossible for humoral 
immunity (i.e. antibodies) to reach them.  Intracellular microorganisms replicate inside 
cells, particularly macrophages, because of the protection that it offers from the immune 
system.  These intracellular pathogens can survive inside macrophages by suppressing the 
innate killing mechanisms.  Cell-mediated immunity has evolved to help deal with this 
problem through T-cell mediated immune responses.  T-cells in the presence of the pro-
inflammatory cytokine IL-12 become Th1 cells that secrete IFN-γ.  IFN-γ along with a 
second signal, usually a TLR agonist, will activate macrophages infected with 
intracellular pathogens.  Activated macrophages make oxygen radicals and NO to help 
enhance parasite killing.  In addition, natural killer (NK) cells are a source of IFN-γ and 





William Leishman and James Donovan each individually discovered parasites of 
the genus Leishmania between 1900-190338.  These single-celled intracellular parasites 
are a member of the order Kinetoplastida and family Trypanosomatidae.  Humans are 
infected by about 21 of 30 Leishmania species that infect mammals.  A few of these 
species include L. major, L. tropica, the L. mexicana complex (L. mexicana, L. 
amazonensis, and L. venezuelensis) and the L. donovani complex (L. donovani, L. 
infantum, and L. chagasi)39;40.  These species can be best distinguished through DNA 
probe analysis, PCR analysis, or ELISA. 
Life cycle 
 Leishmania are dimorphic organisms that exist in two developmental forms: the 
promastigote and amastigote.  During the promastigote phase the parasite is long, slender, 
and flagellated.  The parasite usually exists in its promastigote form when present inside 
the sandfly gut.  During the amastigote form the parasite is oval-shaped and non-motile.  
The parasite exists in this form when present inside macrophages.  Leishmania are 
transferred via sandfly vectors of the genus Phlebotomus and Lutzomyia41;42.  Specifically 
female sandflies, which require blood for egg maturation, transfer Leishmania during 
blood meals.  When an infected sandfly takes a blood meal it transfers Leishmania in its 
promastigote form to the site of the blood meal.  The promastigotes are taken up by 
macrophages, which attempt to destroy the intracellular parasites using the acidic 
environment of the phagolysosome and various degradative enzymes, such as acid 
hydrolases and proteases42.  Despite the harsh conditions of the phagolysosome, the 
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promastigote differentiates into its amastigote form in the acidic environment leading to 
parasite survival43.  Amastigotes replicate, eventually leading to macrophage cell lysis 
and amastigote dispersal to neighboring cells.  The parasite life cycle continues when an 
uninfected sandfly takes a blood meal and ingests amastigotes, which transform into 
promastigotes inside the sandfly gut42 (Figure 4). 
Disease manifestation 
 Leishmaniasis is endemic in 88 countries located throughout 5 continents 
including North and South America, Asia, Africa, and Europe.  The World Health 
Organization (WHO) believes that 12 million humans are infected by Leishmania 
worldwide, including people with no distinct symptoms44.  There are three main 
clinical categories of leishmaniasis: cutaneous, mucocutaneous, and visceral.  Cutaneous 
leishmaniasis exists in two forms, localized cutaneous leishmaniasis (LCL) and diffuse 
cutaneous leishmaniasis (DCL).  In LCL, skin lesions appear at the site of the sandfly 
bite.  The lesions ulcerate, but eventually heal leaving a scar.  L. major, L. amazonensis,  
and L. tropica are known to cause LCL.  In DCL, skin lesions originate the same way that 
LCL lesions develop; however, the DCL lesion eventually spreads to other areas on the 
skin and will not heal without treatment.  L. tropica is most often responsible for DCL 
lesions, although L. amazonensis and L. mexicana are found to cause the disease.  The 
incubation period for cutaneous leishmaniasis can range from 1-2 weeks to 1-2 months45.  
Ninety-percent of cutaneous leishmaniasis cases occur in Afghanistan, Brazil, Iran, Peru, 
Saudi Arabia, and Syria46. 
Mucocutaneous leishmaniasis (MCL) initially resembles the cutaneous form of 









Figure 4.  Leishmania life cycle. (1) Leishmania infected, female sandfly takes a blood 
meal and transfers metacyclic promastigotes to mammalian host.  (2) Macrophage takes 
up promastigote.  (3) Promastigote is exposed to macrophage phagolysosome.  (4) 
Promastigote transforms to amastigote form permitting survival in phagolysosome.  (5) 
Amastigote replicates.  (6) Amastigote replication leads to macrophage lysis.  (7) 
Uninfected sandfly takes a blood meal and ingests amastigotes.  (8) In the sandfly gut, 
each amastigote differentiates into promastigote form preparing for eventual transfer.  












nose, mouth, and throat.  Mucocutaneous lesions are destructive and disfiguring and can 
result in extensive scarring.  The mucocutaneous manifestations of MCL may be due to 
the host immune response to cross-reactive parasite antigens47.  L. braziliensis is known 
to cause mucocutaneous leishmaniasis45.  Ninety-percent of mucocutaneous leishmaniasis 
cases occur in Bolivia, Brazil, and Peru46.  
Visceral leishmaniasis (VL) (also known as kala-azar) is an insidious form of the 
disease.  Many patients with visceral disease fail to realize that they are infected, and the 
disease can be fatal if it goes untreated.  Symptoms of VL include fever, weight loss, 
splenomegaly, hepatomegaly, and anemia.  L. donovani, L. chagasi, and L. infantum are 
known to cause visceral leishmaniasis.  The incubation period of visceral leishmaniasis is 
1-3 months45.  Ninety-percent of visceral leishmaniasis cases occur in Bangladesh, Brazil, 
India, Nepal, and Sudan46.   
Diagnosis & Treatment 
Leishmania infection should be suspected of anyone that lives or has visited a 
Leishmania endemic area and develops a suspicious-looking lesion or experiences 
visceral-like symptoms, which include anemia, splenomegaly, hepatomegaly, fever, and 
weight loss.  Still it is difficult to diagnose leishmaniasis because the cutaneous lesions 
often resemble leprosy or fungal infections, while disease symptoms of visceral 
leishmaniasis can be similar to typhoid, malaria, syphilis, and tuberculosis44. 
The best way to identify a cutaneous infection is to take a biopsy from the edge of 
the lesion and analyze it microscopically for the parasite.  In addition, PCR-based 
methods that amplify mitochondrial (kinetoplast) DNA common to all Leishmania 
species and serodiagnosis can be used to properly diagnose leishmaniasis. 
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There are several current therapies used to treat leishmaniasis, but no vaccine.  
The most commonly used treatment for VL is a 20-28 day intravenous regimen of 
pentavalent antimonials.  Unfortunately, the treatment is not without side-effects 
including nausea, pain, anorexia, myalgia, arthralgia, headache, and malaise.  Two other 
drugs that are more expensive include amphotericin B, a 4-8 week intravenous regimen 
and pentamidine, a 35-63 day intravenous regimen.  A new therapy that was recently 
introduced in June 2002 is miltefosin, a 28-day regimen that is the most affordable of all 
the Leishmania therapies46;48. 
Leishmania molecular genetics 
The Leishmania nuclear genome is approximately 35.5 Mb and organized into 34-
36 chromosomes depending on the species.  The genome contains 58-60% GC content 
and 30% is composed of repeat elements.  None of the Leishmania protein-encoding 
genes contain introns.  Most, if not all, of these genes are initially transcribed into large 
polycistronic precursor RNAs of 60 kb (kilobase) or more and are cleaved into 
monocistronic mRNAs by two intergenic RNA cleavage reactions.  The two reactions 
include trans-splicing of a 39-nt spliced leader sequence (also called a mini-exon) that 
attaches to the 5’ ends of all monocistronic mRNAs and 3’ cleavage/polyadenylation at 
the 3’ ends of mRNAs.  Trans-splicing and polyadenylation are coupled reactions that 
allow the trans-splicing reaction on a downstream gene to be coupled with the 
polyadenylation reaction of the closest upstream gene49;50. 
 Regulation of gene expression in Leishmania is primarily posttranscriptional, 
unlike most prokaryotic and eukaryotic organisms, which primarily regulate genes at the 
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transcriptional level.  Leishmania gene expression is controlled by trans-RNA splicing, 
polyadenylation, mRNA half-lives, protein synthesis, and protein stabilities49;50.  
 Leishmania lack promoters for RNA polymerase II, the enzyme that transcribes 
most protein-encoding genes.  Transcription in these organisms is, however, strand 
specific and is performed by RNA polymerases with α-amanitin-sensitivities similar to 
mammalian RNA polymerases I, II, III.  Promoters for α-amanitin-resistant RNA 
polymerase I activity have been readily detected, as expected, in front of ribosomal RNA 
genes.  A typical α-amanitin sensitive RNA polymerase II activity has been shown to 
transcribe most protein-encoding genes49;50. 
Leishmania evasion of host response 
Leishmania have been shown to primarily infect macrophages51;52 and DCs53.  In 
order to survive long-term, Leishmania must evade cellular microbicidal mechanisms and 
gain entry into an intracellular environment provided primarily by host macrophages. 
 Leishmania uses two major surface molecules for entry into cells.  
Lipophosphoglycan (LPG), the major cell surface glycoconjugate on Leishmania 
promastigotes, plays an active role in protecting parasites from the harsh phagolysosome 
environment54 and is a ligand for several macrophage receptors including the mannose 
receptor, and the β-glucan receptor52.  The major surface protein on Leishmania 
promastigotes, gp63, is a 63 kDa glycoprotein required for cellular entry.  The gp63 
proteolytic activity prevents complement mediated lysis via membrane attack complex55.  
Promastigotes become opsonized with complement proteins and enter macrophages via 
complement receptors (CR)1 and CR356.  In addition, gp63 may be able to bind directly 
to Mac-157 and fibronectin receptors58.  Leishmania does not enter DCs as efficiently as 
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macrophages.  It has been reported that the number of parasites phagocytized by 
macrophages is higher possibly due to fact that the macrophages have higher levels of 
CR3 on their surface than the splenic DCs.  This evidence suggests that macrophages 
may be the preferential target cell for Leishmania59. 
 Macrophages and DCs serve as APCs for naïve T-cells and thus regulate cell-
mediated immunity.  However, Leishmania-infected macrophages generally lack the 
ability to induce primary stimulation of specific naïve T-cells.  This lack of stimulation 
may be due to an active suppression of APC functions by the parasite.  Parasite 
suppression of MHC II synthesis60, parasite inhibition of antigen processing, and MHC II 
loading with immunogenic peptides61;62 along with deficient expression of the co-
stimulatory molecule CD80 have been reported63.  In addition, Leishmania fails to induce 
innate immune responses in infected macrophages.  Parasite infection fails to activate 
NFκB (Mosser Lab, unpublished observations), which is critical for inducing 
proinflammatory cytokines such as IL-12 and TNFα and for inducing co-stimulatory 
molecules on APCs64.  Leishmania infected macrophages not only fail to induce IL-12, 
the main inducer of IFN-γ, Th1 differentiation, and Leishmania resistance65, but actively 
downregulate IL-12 transcription66.  Only Leishmania-infected macrophages that are 
activated by TNFα and IFN-γ to create nitric oxide (NO) can kill intracellular parasites. 
 Despite the inhibitory effect that Leishmania has on macrophage IL-12 
production, in vitro studies have shown that Leishmania-infected DCs are still capable of 
producing IL-1253;67 suggesting that macrophages are exploited to a higher degree than 
DCs.  This may explain the relatively high levels of IFN-γ production observed in human 
cutaneous leishmaniasis.  The DC mechanism for processing the parasite antigen and 
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loading it into the DC MHC II molecules is unknown.  It is also unknown whether the 
parasite is capable of disrupting DC activation, although our lab has developed 
preliminary evidence that is consistent with Leishmania-infected DCs failing to induce 
co-stimulatory molecules on the surface of infected DCs (Mosser Lab, unpublished 
observations). 
IP-10 in leishmaniasis 
IP-10 has been shown to be important in the killing of intracellular parasites by 
virtue of its ability to recruit Th1 effector cells, CD8-positvie T-cells and NK cells68.  All 
these cells produce IFN-γ  that is required for macrophage activation.  Despite IP-10’s 
role in Th1 protection, it has been shown that with high concentrations of exogenous 
recombinant IP-10 Leishmania lesions can actually become larger69.  Our work confirms 
this by showing that IP-10 secreting transgenic parasites cause larger lesions.  This 
unexpected observation can be explained by the work of Bonecchi who showed that 
increasing concentrations of IP-10 led to diminished Th1 migration70.  In addition, others 
have shown that patients with visceral leishmaniasis (VL) have high levels of IP-10 in 
their plasma71, again suggesting that IP-10 may play a role in exacerbating the disease.  
nTreg’s role in leishmaniasis 
Recently, it was discovered that CD4+ CD25+ T-regulatory cells can express 
CXCR3, the receptor for IP-10.  Others have shown that the survival of Leishmania 
parasites in the skin of resistant mice infected with wild-type L. major parasites is 
controlled by a population of CD4+ CD25+ FOXP3+ regulatory T-cells.  These natural 
regulatory T-cells downregulate parasite-specific immunity, thus preventing CD4+ 
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CD25- T-cell mediated elimination of parasites from infected skin.  This is done in both a 
IL-10 dependent and IL-10 independent manner23.  Therefore, the parasites are able to 
persist at small base-line numbers and maintain a sterile cure72.  It is possible that high 
levels of IP-10 can play a role in recruiting the natural T-regulatory cells to the 
Leishmania lesion in order to help maintain disease. 
MCP-1 in leishmaniasis 
 MCP-1 is a CC chemokine known to attract monocytes, DCs, NK cells, and 
memory T-lymphocytes14;26.  Both human monocytes73 and bone marrow derived 
macrophages (BMDM)74 have been shown to produce MCP-1 one hour after L. major 
infection, but the MCP-1 returns to uninduced levels by 4 hours in the BMDM and 12 
hours in human monocytes.   In human leishmaniasis, there is evidence of elevated MCP-
1 levels in localized self-healing cutaneous lesions (LCL).  In contrast, there is no 
detectible MCP-1 in diffuse, non-healing cutaneous lesions75-77.  CCR2, the receptor that 
binds MCP-114;27, has been shown to be vital for host defense to a number of 
pathogens7;78-84.  Likewise, several groups have suggested that MCP-1/CCR2 may play a 
variety of roles in host defense against Leishmania82.  It has been reported that high doses 
of MCP-1 can directly activate anti-Leishmania macrophage killing mechanisms either 
directly85, by inducing reactive oxygen intermediates86, or via nitric oxide production87-89.  
In addition, MCP-1 has been reported to activate NK cells69, which could indirectly 
activate macrophages via IFN-γ production.  Mice normally resistant to L. major 
infection become susceptible when lacking the CCR2 receptor82.  Paradoxically, MCP-1 
KO mice have been shown to develop resistance to Leishmania implicating a possible 
role for MCP-1 in Th2 biasing30.  There are several possible explanations for the 
 25 
 
conflicting phenotypes between Leishmania infected MCP-1 versus CCR2 KO mice.  
These explanations were previously mentioned in the section on MCP-1.  
As mentioned above, previous studies by others have demonstrated the presence 
of MCP-1 during self-healing Leishmania infections, but they did not establish the cause-
and-effect relationship between MCP-1 production, CCR2-positive cellular recruitment, 
and disease resolution.  To recruit CCR2-positive cells into lesions, we developed 
transgenic Leishmania that secrete the murine CC chemokine MCP-1.  Thus, the 
transgenic parasites would secrete MCP-1 and thereby take an active role in manipulating 
immune cell migration into lesions.  We hypothesized that the MCP-1-induced cell 
migration could influence the magnitude and character of the immune response90 and 




CHAPTER 2: MATERIALS AND METHODS 
Animal Studies 
These studies were reviewed and approved by the University of Maryland 
Institutional Animal Care and Use Committee.  BALB/c and C57BL/6 mice were 
purchased from Taconic (Rockville, MD).  CCR2 KO mice on a C57BL/6 background, 
RAG KO mice on a C57BL/6 background, and C5 deficient mice were purchased from 
Jackson Laboratories (Bar Harbor, Maine).  MCP-1 KO mice91 on a BALB/c background 
were obtained from Dr. Barrett Rollins (Harvard Medical School, Boston, MA).          
Cell/parasite culture 
D10 media, which consists of Dulbecco’s modified eagle’s medium (DMEM) 
(Fisher Scientific, Pittsburgh, PA) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (Hyclone, Logan, UT), 100 U/ml penicillin (Fisher Scientific), 100 µg/ml 
streptomycin (Fisher Scientific), and 2mM glutamine (Fisher Scientific), was used for 
culturing peritoneal and bone-marrow derived macrophages.  Both wild-type and 
transgenic parasites were grown in 50:50 media [50% Schneider’s insect medium 
(Sigma-Aldrich, St. Louis, MO) supplemented with 20% FBS, 100 U/ml penicillin, 100 
µg/ml streptomycin, and 2 mM glutamine and 50% M199 media (Invitrogen, Rockville, 
MD)].  Transgenic parasites were grown in the presence of 100 µg/ml nourseothricin 
(SAT) (WERNER BioAgents, Germany).  Leishmania amazonensis axenic amastigotes 
were cultured as previously described92.  Blood agar plates93 were prepared as previously 
described containing SAT.  A concentration of 100 µg/ml SAT was used to select for 
 27 
 
transgenic L. major parasites, while 50 µg/ml SAT was used to select for transgenic L. 
amazonensis parasites. 
Parasites, infection, and parasite quantitation 
Lesion-derived wild-type and transgenic L. major (WHO MHOM/IL/80/Friedlin) 
and L. amazonensis (WHOM/BR/75/Josefa) were isolated from infected mice as 
previously described56.  Mice were injected in the right hind footpad with 1x105 or 5x106 
wild-type or transgenic stationary L. major promastigotes depending on the experiment.  
Lesion size was determined using a caliper to measure the thickness of the infected 
footpad and subtracting the thickness of the contralateral uninfected footpad as described 
previously94.  For ear infections, mice were injected in the right and left ears with 5x104 
wild-type or transgenic L. major parasites.  Ear lesion progression was monitored by 
measuring the diameter of the lesion using an Absolute Digimatic Caliper (Mitutoyo, 
Ontario, Canada) as previously described72.  For protection experiments, C57BL/6 mice 
were infected with 5x104 wild-type L. major or transgenic L. major MCP-1 parasites in 
the right footpad.  After 5 weeks, these mice along with non-infected (unprotected) mice 
were infected in both ears with 1x105 wild-type L. major parasites and monitored for 
lesion development over the next 5 weeks.  For all the in-vivo experiments, error bars 
represent the standard error of the mean of three separate experiments done with a 
minimum of five mice per group.   
Parasite burdens were determined by serial dilution of single cell suspensions 
made from excised footpads, ears, lymph nodes, or spleens as previously described94. 
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Gene Splicing by Overlapping Extension (SOE) PCR 
Two different PCR products were created in separate PCR reactions and used to 
generate a hybrid SOE PCR product95;96 that begins with a 5’-SmaI restriction site 
followed by the L. major gp63 signal sequence and the entire murine MCP-1/JE gene and 
ends with a 3’-SmaI site.   
The first PCR reaction generated a 148 basepair (bp) PCR product that contained 
a 5’-SmaI restriction site followed by the L. major gp63 signal sequence and a short 
sequence corresponding to the murine MCP-1/JE gene.  This fragment was created using 
the following primers: sense 5’-TATCCCGGGATGTCCGTCGACAGCAG-3’ and 
antisense 5’-GCATGACAGGGACCTGAGCGGCGTGTGCCCACGC-3’.  These 
primers were used along with a plasmid template that contained the entire L. major gp63 
gene (accession #: Y00647).  After the gp63 PCR #1 product was generated, it was gel 
purified using a gel extraction kit (Qiagen, Valencia, CA).  The second PCR reaction 
generated a 450 bp PCR product that contains the murine MCP-1/JE gene, followed by a 
3’-SmaI restriction site, using the following primers:  sense 5’-
GCTCAGGTCCCTGTCATGCTTCTGGGC-3’ and antisense 5’-
TACCCGGGGTTCACTGTCACACTGGTCACTCCTAC-3’.  These primers were used 
along with the template pORF-mMCP-1 (Invivogen, San Diego, CA) to create MCP-1 
PCR #2.   
The hybrid PCR product MCP-1SOE was created using gp63 PCR #1 and MCP-1 
PCR #2 as templates.  A series of short melting (95 °C) and extension (72 °C) steps were 
performed prior to running the full PCR cycle.  The two templates were added alone prior 
to the addition of Taq polymerase, primers, and deoxynucleotide triphosphates (dNTPs) 
 29 
 
in order to generate a few hybrid templates before starting the true PCR cycling.  The 
PCR product was purified using a PCR purification kit (Qiagen) and ligated into the TA 
cloning vector, pCRII (Invitrogen). 
The hybrid PCR product was excised from the TA cloning vector with SmaI, gel 
purified, and ligated into the multiple cloning site of the Leishmania expression plasmid, 
pIR1SAT, which was generously provided by Dr. Steven Beverley (Washington 
University, St. Louis, MO).  The ligated expression plasmid, pIR1SAT-MCP-1/JE was 
transformed into Max Efficiency DH10B competent cells (Invitrogen) by Heat-shock 
method.  The pIR1SAT-MCP1/JE plasmid was isolated from DH10B cells using a 
plasmid maxi kit (Qiagen), digested with SwaI, and transfected into Leishmania parasites 
to permit integration into the parasite genome.  The same approach was taken to create 
pIR1SAT-IP-10 and integrate it into the Leishmania genome. 
Transfection of Leishmania 
L. major or L. amazonensis parasites (1x108 parasites) were resuspended in 400 µl 
of electroporation buffer [21 mM HEPES (pH 7.5), 137 mM NaCl, 5 mM KCl, 0.7 mM 
Na2PO4, and 6 mM glucose].  This suspension was mixed with 5 µg of linearized 
pIR1SAT-MCP-1/JE, added to a 0.4 cm Gene Pulser cuvette (BIORAD, Hercules, CA), 
and electroporated (0.5 kV, 0.5 µFd) using BIORAD’s Gene Pulser II.  The cuvette was 





RNA was isolated from 1x106 wild-type or transgenic L. major or L. amazonensis 
parasites during either promastigote or axenic development using Trizol RNA prep 
(Invitrogen).  The RNA was converted to cDNA using the manufacturer’s protocol.  
Murine MCP-1/JE was amplified from the cDNA samples using the following primers:  
sense 5’-GCTCAGGTCCCTGTCATGCTTCTGGG-3’ and antisense 5’-
GTTCACTGTCACACTGGTCACTCCTAC.  gp63 was amplified using the following 
primers:  sense 5’-ATCCTCACCGACGAGAAGCGCGAC-3’ and antisense 5’-
ACGGAGGCGACGTACAACACGAAG-3’.   
Transgenic MCP-1 detection 
Costar high-binding ELISA plates (Fisher Scientific) were coated with 
monoclonal goat anti-mouse MCP-1/JE antibody (capture antibody) from the DuoSet 
MCP-1/JE ELISA kit (R&D systems, Minneapolis, MN).  Wild-type and transgenic 
parasites (5x106) were added to the ELISA plate wells for 24 hours.  The following day, 
the parasites were washed away and the MCP-1 ELISA was completed according to the 
manufacturer’s protocol using biotinylated anti-mouse MCP-1/JE detection antibody, 
streptavidin-horseradish peroxidase (HRP), and HRP substrate. 
MTT assay 
Parasite viability and metabolism was measured using an MTT assay as 
previously described97.  Briefly, wild-type and transgenic parasites (1x106) were grown in 
50:50 media.  During the first seven days, 100 µl of the parasite culture was removed and 
added to a 96-well plate in triplicate.  20 µl of MTT [3-(4,5-dimethylthiazolyl-2)-2,5 
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diphenyltetrazolium bromide] (Sigma-Aldrich )(5mg/mL) was added to the 100 µl 
parasite culture for 2 hours at room temperature followed by 100 µl of DMSO (Sigma-
Aldrich) for an additional 1 hour.  The absorbance was then measured at 550 nm. 
Leishmania survival assay and staining 
Peritoneal macrophages were isolated from mouse peritoneal cavities using cold 
PBS as previously described56.  Macrophages (1x105) were added to coverslips in 100 µl 
bubbles for 2 hours to allow macrophage attachment.  D10 media was added and the cells 
were rested for 2 hours.  Prior to infection, parasites were opsonized with 10% serum 
from C5 deficient mice for 20 minutes at room temperature.  The peritoneal macrophages 
were then infected at a multiplicity of infection (MOI) of 10:1 using opsonized wild-type 
or transgenic parasites for 2 hours.  Cells were washed and fixed with methanol for 10 
minutes immediately after infection or after further 72 hours of incubation.  The 
experiment was also performed using lesion-derived amastigotes from either wild-type or 
transgenic infected CCR2 KO mice.  The amastigotes were used at an MOI of 10:1 and 
added for 1 hour before washing.  Cells were fixed immediately after 1 hour of infection 
or after further 72 hours of incubation.  For immunofluoresence visualization, glass 
coverslips were blocked with PBS containing 5% FBS.  Mouse anti-Leishmania serum 
(1:250) was used to stain Leishmania amastigotes for 1 hr at 4 °C.  The coverslips were 
then washed twice and a fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
IgG (H+L) (1:100) was added for 30 minutes.  After the coverslips were washed again, 
they were treated with a 1:1000 dilution of 1 mg/ml propidium iodide for 2 minutes.  




Intracellular staining of parasite-derived MCP-1 
 Bone-marrow derived macrophages (BMDM) were prepared from MCP-1 KO 
mice as previously described98.  Macrophages were plated, infected for 48 hours with 
C5d serum opsonized wild-type or transgenic MCP-1 parasites, and fixed as described 
above.  Coverslips were blocked with 6% bovine serum albumin (BSA) for 1 hour prior 
to staining.  Parasite-derived MCP-1 was stained using 100 ng/mL goat anti-mouse MCP-
1 antibody (R&D systems) for 45 minutes at 4 ºC  followed by tetramethylrhodamine 
isothiocyanate (TRITC)-conjugated donkey anti-goat IgG (Jackson ImmunoResearch) 
(1:100) for 30 minutes at 4 ºC.  The parasites were then stained as described above using 
mouse anti-Leishmania serum for 45 minutes along with FITC-conjugated rabbit anti-
mouse IgG (Jackson ImmunoResearch) (1:100) for 30 minutes at 4 ºC.  The macrophage 
nucleus was stained with Hoechst stain (1:4000) for 2 minutes.  Coverslips were mounted 
as described above. 
Thymidine incorporation assay 
Lymph node cells were isolated from C57BL/6 mice that were infected with wild-
type or transgenic L. major parasites in the footpad.  After 1,  2, and 3 weeks post-
infection, cells (5x105) from each group were added to a 96-well round bottom plate and 
stimulated with 25 µg soluble Leishmania antigen (SLA) for 72 hours.  After 72 hours, 1 
µCi Thymidine (3H) (MP Biomedicals Inc., Irvine, CA) was added to each well and 
mixed with the stimulated and non-stimulated lymphocytes for 6 hours.  Proliferation was 
measured using a cell harvester 96 (Tomtec, Hamden, CT) and 1450 Microbeta Trilux 
liquid scintillation and luminescence counter (EG&G Wallac, Finland).  SLA was 




IFN-γ and IL-4 were measured from supernatants of SLA stimulated lymphocytes 
by sandwich ELISA using capture (clone R4-6A2) and detection (clone XMG1.2) anti-
IFN-γ antibodies and capture (clone 11B11) and detection (clone BVD6-24G2) anti-IL-4 
antibodies (BD Pharmingen, San Diego, CA). 
Isolation of cells from infected mouse ears 
Ears infected with wild-type or transgenic L. major MCP-1 parasites were 
excised, soaked in 70% ethanol, and air-dried for 5-10 minutes.  The ears were then split 
into ventral and dorsal portions and placed in liberase (5mg/mL) (Roche, Indianapolis, 
IN) diluted 1:100 in PBS for 2 hours at 37 ºC as previously described72.  The ears were 
put into a 50 µM medicon homogenizer (BD biosciences) with 1 ml PBS and 
homogenized in BD’s Medimachine (BD biosciences) for 1 minute.  The liquefied, 
homogenized ears were then passed through a 50 µM syringe filcon filter (BD 
biosciences) and centrifuged at 300g for 10 minutes.  The cells isolated from the ears 
were then resuspended in PBS containing 5% FBS and 5mM EDTA and labeled with 
antibodies for flow cytometry.   
Flow Cytometry 
Cells isolated from ears were labeled with the following antibodies: PE 
conjugated anti-mouse F4/80 (clone BM8, eBioscience, San Diego, CA), PerCp-Cy5.5 
conjugated anti-mouse CD11b (clone M1/70), and FITC conjugated anti-mouse Gr-1 
(clone RB6-8C5)(BD Pharmingen).  MC-21 (rat anti-mouse CCR2)100 was provided by 
Dr. Matthias Mack (University of Munich, Germany) and used along with the secondary 
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antibody FITC conjugated goat anti-rat Ig (BD biosciences) to identify CCR2-positive 
cells.  Cells were sorted using BD FACSAria (BD biosciences) at Johns Hopkins 
Bloomberg School of Public Health. 
Staining sorted, infected CCR2-positive macrophages 
Sorted CCR2-positive macrophages were cytospun using Cytospin 4 (Thermo 
Shandon, Pittsburgh, PA) at 600 rpm for 6 minutes.  Cells were fixed with methanol and 
then stained in 1:20 diluted Giemsa stain (Sigma-Aldrich) for 20-30 minutes.  The 
number of parasites per 100 CCR2-positive macrophages was counted with a maximum 
of 10 parasites per macrophage as a limit for heavily infected macrophages. 
MCP-1 co-activation in-vitro studies 
Mice were injected intraperitoneally (i.p.) with 1 ng of recombinant  MCP-1 
(Peprotech Inc., Rocky Hill, NJ) or with PBS.  Three days later peritoneal macrophages 
were isolated from both groups and plated as described above.  Macrophages were treated 
with 100 U IFN-γ, 1 ng MCP-1, or both IFN-γ and MCP-1 for 10 hours.  The cells were 
then washed twice with warm PBS and fresh D10 was added.  Infection was done with an 
MOI 10:1 of wild-type L. major parasites for 2 hours.  Staining was performed as 
described above.  Intracellular survival was analyzed at 0 and 72 hours post-infection. 
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CHAPTER 3: THE GENERATION OF CHEMOKINE-
SECRETING LEISHMANIA PARASITES 
 
SOE-PCR and Plasmid Construction 
Previously, our lab made the observation that Leishmania parasites infect 
macrophages via a quiesent mechanism and do not induce the proinflammatory cytokines 
IL-12 and TNF-α due to a failed NFκB translocation (data not shown).  Based on these 
earlier studies we became interested in genetically engineering chemokine-secreting 
parasites that would recruit immune cells to the site of infection.  These parasites were 
engineered by first using a technique called Gene Splicing by Overlap Extension (SOE-
PCR).  In SOE-PCR, two different PCR products were created in separate PCR reactions 
and used together as templates to generate a hybrid SOE PCR product (Figure 5).  This 
approach has been shown to avoid the need for repeated digestions and ligations during 
regular cloning95;96.  The first hybrid SOE-PCR product to be constructed was MCP-
1SOE, a 579 base pair (bp) PCR product that began with a 5’-SmaI restriction site 
followed by the Leishmania gp63 signal sequence and the entire murine MCP-1 gene and 
ended with a 3’-SmaI restriction site.  The gp63 signal sequence portion of MCP-1SOE 
was required for protein transport and protein secretion, while the murine MCP-1 gene 
sequence encoded the chemokine MCP-1. 
 The second hybrid SOE-PCR product constructed was IP-10SOE, a 426 bp PCR 
product that was constructed in the same manner as described above except that the gp63 
signal sequence was attached to the entire murine IP-10 gene. 








gp63 PCR #1 MCP-1 PCR #2
MCP-1SOE  
Figure 5.  Gene Splicing by Overlap Extension.  gp63 PCR#1 and MCP-
1 PCR#2 were created in separate PCR reactions.  Both PCR products were 





After MCP-1SOE and IP-10SOE were generated via PCR they were ligated into a TA 
vector.  MCP-1SOE and IP-10SOE were then cut from the TA vector by digestion and 
ligated into the Leishmania expression plasmid pIR1SAT, creating pIR1SAT-MCP-1 
(Figure 6) and pIR1SAT-IP-10 (plasmid not shown).  The Leishmania expression 
plasmid pIR1SAT contains several key components.  First, it contains a multiple cloning 
site to ligate in the hybrid PCR products.  Second, it contains a streptothricin (SAT) 
resistance marker for selection purposes.  Finally, the plasmid contains the 5’ and 3’ 
portion of the L. major 18S ribosomal RNA subunit on opposite ends of the plasmid.  
Therefore, we were able to digest both pIR1SAT-MCP1 and pIR1SAT-IP10 with the 
restriction enzyme SwaI and linearize the plasmids so that the 5’ and 3’ portions of the 
18S rRNA genes were on opposite sides of the linearized plasmid for easy integration 
into the Leishmania genome (Figure 7). 
Transgenic Leishmania parasites secreting MCP-1 
Transgenic L. major MCP-1 (Lm-Tg) and L. amazonensis-MCP-1 (La-Tg) 
transcribed MCP-1 mRNA during the promastigote stage of development (Figure 8).  
Wild-type (WT) non-transfected parasites did not transcribe MCP-1 mRNA as expected.  
Axenically grown amastigotes of transgenic L. amazonensis MCP-1 also transcribed 
murine MCP-1 (Figure 8).  The level of MCP-1 produced by these parasites during the 
extracellular promastigote stage of development was measured by ELISA.  Transgenic L. 
major MCP-1 and L. amazonensis MCP-1 secreted 161 + 14.6 and 199 + 51 pg/ml 
respectively (Figure 9).  Wild-type parasites produced no detectible MCP-1, as expected.  
The two clones represented in Figure 9 secreted the highest level of MCP-1 of the 









 Figure 6.  pIR1SAT-MCP-1.  The plasmid contains a multiple 
cloning site for insertion of the MCP-1SOE hybrid product.  The 
multiple cloning site is flanked by genes involved in transplicing 
and polyadenylation.  The plasmid contains a streptothricin 
(SAT) resistance marker.  The plasmid also contains the 5’ and 
3’ portions of the L. major 18S ribosomal RNA subunit (SSU) 
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 Figure 7.  Integration of linearized pIR1SAT-MCP-1 into the Leishmania 
genome.  pIR1SAT-MCP-1 was linearized using the restriction enzyme SwaI.  After 
linearization, the 5’ and 3’ portions of the 18 S ribosomal RNA subunit were on 
opposite sides of the linearized plasmid.  Leishmania parasites were transfected with 


























Figure 8.  Transgenic parasites transcribe MCP-1 mRNA.  Total RNA 
was isolated from wild-type and transgenic MCP-1 parasites during 
promastigote development.  Murine MCP-1/JE was amplified from the 
cDNA of transgenic L. major MCP-1 (Lm-Tg) and L. amazonensis MCP-1 
(La-Tg) parasites, but not from the cDNA of wild-type L. major (Lm-WT) 
or L. amazonensis (La-WT).  Axenically grown L. amazonensis MCP-1 and 
wild-type L. amazonensis amastigotes were also analyzed.  MCP-1/JE was 
amplified from transgenic amastigotes, but not from the wild-type.  The 
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Figure 9.  Transgenic MCP-1 parasites secrete MCP-1.  
A total of 5x106 Lm-Tg, Lm-WT, La-Tg, or La-WT 
parasites were added to an ELISA plate coated with 
monoclonal goat anti-mouse MCP-1 antibody.  After 24 




secrete MCP-1 in-vivo, BALB/c mice were infected with transgenic MCP-1 parasites and 
four weeks later the parasites were isolated from footpads and screened for MCP-1 
production.  Despite the absence of antibiotic selective pressure in the mouse, the 
transgenic MCP-1 parasites isolated from infected footpads continued to secrete high 
levels of MCP-1 after isolation (Figure 10).  This expression in the absence of selection is 
consistent with the stable integration of the linearized constructs into the 
Leishmania genome. 
The presence of parasite-derived MCP-1 was examined in L. major MCP-1 
infected BMDM from MCP-1 KO mice.  Parasite-derived MCP-1 was detected in the 
cytoplasm of Lm-Tg infected BMDM (Figure 11A), but not in wild-type infected 
macrophages (Figure 11B) confirming that the transgenic MCP-1 parasites are capable of 
secreting MCP-1 during their intracellular stage of development.  MCP-1 was not 
detected in the supernatants of Lm-Tg infected BMDM (MCP-1 KO) by ELISA during 
various time points up to 96 hours post-infection (Figure 12).  However, considerable 
amounts of MCP-1 (318 + 3 pg/ml) were detected in the supernatants after the Lm-Tg 
infected macrophages were lysed at 96 hours post-infection.  Macrophages infected with 
wild-type parasites did not release MCP-1 after lysing as expected (Figure 12).  These 
results suggest that the parasite-derived MCP-1 does not leak out of the infected cells and 
must be released at the same time the amastigotes are released when they burst free from 
infected cells. 
Transgenic parasites secrete IP-10 
 
 We also engineered an IP-10 secreting parasite.  Transgenic L. major IP-10 (Lm-









































 Figure 10.  MCP-1 production from footpad-derived parasites.  
MCP-1 production by transgenic L. major MCP-1 parasites grown 
in culture (Tg-C, open bars) was determined by ELISA.  MCP-1 
production by transgenic parasites isolated from two different mice 
infected 4 weeks prior (Tg-M1 and Tg-M2, striped bars) or wild-


















Figure 11.  Parasite-derived MCP-1 expressed during intracellular growth. 
Bone-marrow derived macrophages (BMDM) from MCP-1 KO mice were infected with (A) Lm-Tg 
or (B) Lm-WT parasites at an MOI for 10:1.  After 48 hours, the infected cells were washed, fixed 
with methanol, and stained with separate polyclonal antibodies against Leishmania (stained green) 









































 Figure 12.  Intracellular accumulation of parasite-derived MCP-1.  
MCP-1 KO BMDM were infected at an MOI of 10:1 using Lm-WT or 
Lm-Tg parasites.  Supernatants were collected at 0 and 96 hours (96-S) 
post-infection.  In addition, cells infected for 96 hours were lysed (96-
L) using 0.01% Triton X + 5mM MgCl2 in H20.  An MCP-1 ELISA 
















of development (Figure 13A).  The wild-type L. major parasites were unable to transcribe 
IP-10 mRNA.  In addition, transgenic L. major IP-10 were capable of secreting low 
levels of IP-10 (35 pg), while the wild-type parasites secreted no IP-10 protein (0 pg) 
(Figure 13B). 
Transgenic parasites are as healthy as wild-type parasites 
 The metabolic activity of the transgenic parasites was evaluated and compared to 
wild-type parasites by measuring their ability to reduce MTT to formazan.  Both 
transgenic L. major MCP-1 and L. major IP-10 were able to reduce MTT to formazan.  
The rate and extent of MTT reduction was not different between wild-type and transgenic 
parasites (Figure 14).  To determine whether the transgenic parasites were equally as 
infective as wild-type parasites, we infected resting resident peritoneal macrophages with 
both transgenic parasites and compared their intracellular survival to wild-type parasites 
72 hours later.  Equal numbers of infected macrophages were found at 0 hours (data not 
shown).  At 72 hours, there was an equivalent number of wild-type L. major (Figure 15 
A), L. major MCP-1 (Figure 15B), and L. major IP-10 (Figure 15C) parasites present 
inside macrophages (Table 1).  Similar results were obtained with the amastigote form.  
The numbers of wild-type and transgenic MCP-1 amastigotes present inside infected 
macrophages were similar at 1 hour post-infection (data not shown), and these numbers 
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 Figure 13.  Transgenic IP-10 secreting parasites transcribe IP-10  
mRNA and secrete IP-10 protein.  (A) Total RNA was isolated 
from wild-type and transgenic IP-10 parasites during promastigote 
development.  Murine IP-10 was amplified from the cDNA of 
transgenic L. major IP-10 (Lm-TgIP-10) parasites, but not from the 
cDNA of wild-type L. major (Lm-WT).  The gene gp63 was 
amplified from the cDNA as a loading control.  (B) A total of 
5x106 Lm-TgIP-10, or Lm-WT parasites was added to an ELISA 
plate coated with monoclonal goat anti-mouse IP-10 antibody.  
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Figure 14.  Transgenic parasites are as healthy as wild-type. 
Wild-type L. major (closed circles), L. major MCP-1 (open 
circles), and L. major IP-10 (open triangles) (1x106) were added 
to separate flasks.  On days 0-7, 100 µl aliquots were taken from 
each parasite culture, mixed with 20 µl MTT (5 mg/ml), and 
added to a 96-well round bottom plate for 2 hours at room 
temperature.  After the incubation period, 100 µl DMSO was 
added to each well and the plate was incubated for 1 hour at 
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 Figure 15.  Transgenic parasites efficiently infect monolayers of resident 
macrophages.  Peritoneal macrophages (1x105) were infected at an MOI of 10:1 
for 2 hours with (A) wild-type L. major, (B) L. major MCP-1, or (C) L. major 
IP-10 promastigotes.  After a 72 hour incubation, monolayers were washed, 
fixed, and stained with a polyclonal antibody to Leishmania (stained green).  



































TABLE 1.   Transgenic parasites efficiently infect monolayers of resident macrophages 
 






with 4 > parasites 
 




83 ± 4 
 
255 ± 11 
 
33 ± 4 
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258 ± 20 
 
34 ± 4 
 





87 ± 3 
 
271 ± 19 
 
37 ± 7 







































 Figure 16.  Transgenic MCP-1 amastigotes are equally as infective as wild-type 
amastigotes.  Peritoneal macrophages (1x105) were infected using lesion-derived 
amastigotes from either (A) wild-type L. major or (B) transgenic L. major MCP-1 infected 
CCR2 KO mice.  The amastigotes were used at an MOI of 10:1 and added for 1 hour 








TABLE 2.   Transgenic MCP-1 amastigotes are equally as infective as wild-type amastigotes 
 






with 4 > parasites 
 




87 ± 11 
 
284 ± 21 
 
38 ± 6 
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274 ± 29 
 
32 ± 3 













We developed two transgenic Leishmania parasites that secrete either the murine 
CC chemokine MCP-1 or CXC chemokine IP-10.  Both transgenic parasites thereby 
could take an active role in manipulating immune cell migration into lesions.  Other 
groups have engineered transgenic parasites in the past101-104, but never has a parasite 
been constructed that was shown to recruit innate immune cells to the site of infection.  
We hypothesized that the chemokine induced cell migration created by either transgenic 
parasite could influence the magnitude and character of the immune response, and 
thereby affect the outcome of disease. 
  By all criteria available to us, the transgenic parasites that we developed appear 
to be as healthy as wild-type parasites.  They grow in culture with the same kinetics and 
to the same density (data not shown).  They reduce MTT to formazan and they invade 
and persist in resting peritoneal macrophages similar to wild-type parasites.   
The transgenic MCP-1 parasites are capable of transcribing MCP-1 mRNA and 
secreting MCP-1 protein.  The MCP-1 protein was secreted during both the extracellular 
and intracellular stages of development.  No MCP-1 was detected in the supernatant of 
MCP-1 KO macrophages following infection with transgenic MCP-1 parasites.  
However, when the cells that had been infected with transgenic MCP-1 parasites for 96 
hours were lysed, then parasite-derived MCP-1 was released from the infected cells.  We 
believe that MCP-1 is secreted by the transgenic MCP-1 parasites into the macrophage 
cytoplasm and that the MCP-1 accumulates within infected cells.  When the cells burst 
due to overwhelming parasite replication then the parasite-derived MCP-1 spills out of 
the infected cell. 
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Transgenic IP-10 secreting parasites were also engineered to recruit immune cells 
to the site of infection.  We hypothesized that the immune cell recruitment in response to 
the IP-10 secreting parasites would be distinct from the MCP-1 secreting parasites and 
that this recruitment could lead to a different phenotype in mice infected with transgenic 





















CHAPTER 4: TRANSGENIC MCP-1 PARASITES CAUSE A 
HEALING PHENOTYPE IN MICE; TRANSGENIC IP-10 
PARASITES CAUSE A NON-HEALING PHENOTYPE 
 
Lack of lesion development in mice infected with L. major MCP-1 
MCP-1 secreting parasites were engineered and demonstrated to secrete MCP-1 
protein during both stages of development.  We were interested in determining whether 
the MCP-1 producing parasites would have any effect when injected into mice.  We 
infected BALB/c mice in the hind footpad with 1x105 transgenic L. major- MCP-1 or 
wild-type L. major parasites and monitored lesion development over 35 days.  The 
transgenic L. major MCP-1 caused little to no detectable lesions, with the mean peak 
swelling of only 0.14 + 0.03 mm (Figure 17).  In contrast, wild-type L. major infected 
mice developed progressively larger lesions, which reached an average diameter of 4.95 
+ 0.15 mm.  When parasites were isolated from the foot, lymph node, and spleen after 35 
days,  there were significantly fewer parasites in the foot of the transgenic L. major MCP-
1 infected mice (274 + 38 parasites) compared to the wild-type infected mice (2.17x108 + 
6x107 parasites) (Figure 17, inset).  There were also fewer parasites in the lymph nodes 
(54 + 23 compared to 1.22x105 + 3.7x104), and no transgenic parasites were detected in 
the spleen.  In initial infectivity experiments, L. major that were transfected with the 
empty plasmid (L. major pIR1SAT) were also used.  They caused lesions that were 
comparable in size to wild-type infected mice and had comparable numbers of parasites 
(data not shown).   
A similar infection was performed in mice lacking the MCP-1/JE gene91.  Similar 
























































Figure 17.  Lack of lesion development in Lm-Tg infected BALB/c 
mice.  Lesion size of BALB/c mice infected with 1x105 Lm-WT 
parasites in the footpad (closed circles) were compared with those of 
BALB/c mice infected with Lm-Tg (open circles).  Lesions were 
measured at weekly intervals.  Parasite burdens (inset) were 
determined for Lm-WT (solid bars) and Lm-Tg (open bars) on day 35 
post-infection by limiting dilution assays.  Parasite burdens in 
footpads, lymph nodes (LN), and spleens were determined.  Error bars 
represent the standard error of the mean of three separate experiments 








lesions (0.12 + 0.02 mm) by day 35 following infection with L. major-MCP-1 (Figure 
18).  They also had minimal to no parasites in their feet (37 + 13), lymph nodes (50 + 
15), or spleens (0+ 0) (Figure 18, inset).  Infection of the MCP-1 KO mice with wild-type 
L. major resulted in substantial lesion development (4.47 + 0.43 mm) and higher numbers 
of parasites in the foot (4.43x107 + 1.45x107), lymph node (2.66x106 + 8.8x105), and 
spleen (4300 + 1914).  These results suggest that parasite-derived MCP-1 was sufficient 
to induce the healing phenotype that was observed following infection with transgenic L. 
major MCP-1. 
To evaluate the infectivity of our transgenic parasites in a more resistant strain of 
mouse, we proceeded with infections in C57BL/6 mice.  These mice were infected in the 
hind footpad with 5x106 transgenic L. major-MCP-1 or wild-type L. major parasites and 
lesion development was monitored over the course of 31 days.  The transgenic parasites 
caused essentially no lesions (0.12 + 0.01 mm), while the mice infected with Lm-WT 
developed lesions that reached maximum size on day 21 (2.41 + 0.04 mm) (Figure 19A).  
Consistent with the healing phenotype of these mice, lesions had diminished to 1.87 + 
0.02 mm on day 31 post-infection.  Mice infected with transgenic parasites contained 
fewer parasites in the foot (108 + 23), lymph node (74 + 13), and spleen (0+ 0) compared 
to mice infected with Lm-WT; foot (4.85x106 + 5.5x105), lymph node (1.9x104 + 
6.54x102), and spleen (52 + 7) (Figure 19B).  Thus, mice that are relatively resistant to 
infection with wild-type L. major parasites show significantly higher resistance to 



























































  Figure 18.  Lack of lesion development in MCP-1 KO 
mice infected with Lm-Tg.  MCP-1 KO mice on a BALB/c 
background were infected with 1x105 Lm-WT (closed circles) or Lm-
Tg (open circles).  Lesions were measured in weekly intervals.  Parasite 
burdens (inset) were determined on day 35 post-infection for Lm-WT 
(solid bars) and Lm-Tg (open bars).  Error bars represent the standard 
error of the mean of three separate experiments done with a minimum 


































































  Figure 19.  Lack of lesion development in C57BL/6 mice infected with  
Lm-Tg.  (A) C57BL/6 mice were infected with 5x106 Lm-WT (closed circles) or Lm-Tg 
(open circles) and lesion development was measured at weekly intervals.  Parasite burdens 
were quantitated on day 31 post-infection for C57BL/6 mice infected with Lm-WT (solid 
bars) and Lm-Tg (open bars).  Error bars represent the standard error of the mean of three 













Transgenic L. major IP-10 are hypervirulent  
 
Transgenic IP-10 secreting parasites were used to infect BALB/c and C57BL/6 
mice in separate in-vivo experiments.  BALB/c mice were infected in the footpad with 
1x105 L. major IP-10 parasites and compared to wild-type L. major infected BALB/c 
mice.  The transgenic L. major IP-10 caused larger lesions, with the mean peak swelling 
of 4.97 + 0.21 mm on day 35 post-infection (Figure 20A) compared to mice infected with 
wild-type L. major, which had a mean peak swelling of 3.25 + 0.19 mm.  Parasites were 
isolated from the foot on day 35 post-infection.  There were significantly more parasites 
in the foot of those mice infected with the IP-10 secreting parasites compared to mice 
infected with the wild-type parasite (3.51x108 + 5.5x107 compared to 1.1x107 + 1.5x107) 
(Figure 20B)     
C57BL/6 mice were also infected with 5x106 L. major IP-10 parasites and 
compared to mice infected with wild-type parasites. Wild-type parasites caused lesions of 
1.83 + 0.13 mm on day 31 post-infection.  Transgenic L. major IP-10 parasites caused 
large lesions with the mean peak swelling of 5.07 + 0.38 mm (Figure 21A).  These 
infected mice were monitored biweekly and lesion development was monitored for 31 
days.  At the end of 31 days parasite burdens were prepared from mice infected with 
transgenic IP-10 parasites and compared to wild-type infected mice.  The C57BL/6 mice 
infected with transgenic IP-10 parasites contained significantly higher numbers of 
parasites in the infected foot (5.39x108 + 3.24x108), lymph node (1.1x106 + 5.6x105), and 
spleen (6250 + 551) compared to mice infected with wild-type parasites; foot (5.93x106 + 




























































Figure 20.  L. major IP-10 are hypervirulent.  (A) BALB/c mice were infected with 1x105 
Lm-WT (closed circles) or Lm-TgIP-10 (open triangles) and lesion development was 
measured at weekly intervals.  (B)  Parasite burdens were quantitated on day 35 post-
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  Figure 21.  L. major IP-10 causes significantly larger lesions in resistant C57BL/6 mice.             
(A) C57BL/6 mice were infected with 5x106 Lm-WT (closed circles) or Lm-TgIP-10 (open 
triangles) and lesion development was measured at weekly intervals.  Parasite burdens were 
quantitated on day 31 post-infection for C57BL/6 mice infected with Lm-WT (solid bars) and 














 The transgenic MCP-1 secreting parasites caused minimal disease in several 
strains of mice.  BALB/c mice, which are normally susceptible to L. major infection, did 
not develop lesions when infected in the footpad, nor did these parasites efficiently 
disseminate to other organs, as did wild-type parasites.  Transgenic MCP-1 parasites were 
also attenuated in MCP-1 deficient mice suggesting that parasite-derived MCP-1 was 
responsible for the attenuated phenotype.  Others have demonstrated that wild-type 
Leishmania parasites can induce MCP-1 production 1 hour after infection and that the 
MCP-1 levels return to uninduced a few hours later73;74.  Therefore, reproducing the 
healing phenotype in MCP-1 KO mice infected with Lm-Tg was important to prove that 
the parasite-derived MCP-1 was the cause of the healing phenotype and not host MCP-1.  
Transgenic parasites also failed to cause lesions in C57BL/6 mice that are resistant to L. 
major infection, even with high doses of transgenic L. major MCP-1.  Normally C57BL/6 
mice infected with wild-type parasites develop lesions and eventually resolve the lesions.  
However, C57BL/6 mice infected with Lm-Tg were even more resistant and failed to 
develop lesions.  We have tried to reproduce the healing phenotype in the footpad by 
using high amounts of recombinant MCP-1 prior to Leishmania infection, but were not 
successful (data not shown).  This may indicate that the constitutive expression of MCP-1 
by the transgenic parasites is important for the continued recruitment of immune cells 
into lesions. 
 The transgenic IP-10 secreting parasites caused large lesion development in both 
BALB/c and C57BL/6 mice.  Much to our surprise, the C57BL/6 mice infected with 
transgenic IP-10 parasites developed large lesions that did not appear to resolve like the 
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wild-type infected C57BL/6 footpads.  The disease exacerbation that occurs in C57BL/6 
infected with Lm-TgIP-10 is worse than the exacerbation in BALB/c mice infected with 
Lm-TgIP-10.  BALB/c mice infected with wild-type L. major develop a Th2 response 
that results in high levels of IL-4 production and a lack of intracellular parasite killing.  
Ultimately, this results in the mouse’s death.  C57BL/6 mice infected with wild-type L. 
major develop a Th1 response that results in high levels of IFN-γ production and the 
activation of macrophage intracellular parasite killing mechanisms, which controls the 
disease and leads to disease resolution.  The hypervirulent Lm-TgIP-10 causes an 
additive effect in BALB/c mice and further impairs the disease.  However, the 
hypervirulent Lm-TgIP-10 has a more profound effect in C57BL/6 mice by causing very 
large lesions that do not appear to resolve.  Instead, these lesions continue to increase 
over time and the mice appear unable to control the infection despite developing a Th1 
response.  We hypothesized that a population of cells was migrating into the footpad and 
exacerbating the disease.  Recently, it was discovered that nTregs express CXCR3, the 
receptor for IP-10, on their surface.  nTregs have been shown to produce high levels of 
IL-10 during leishmaniasis.  It is possible that the transgenic IP-10 secreting parasites are 
recruiting nTregs, which are producing IL-10 and exacerbating the disease. 
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CHAPTER 5:  CHARACTERIZATION OF HEALING 
PHENOTYPE CAUSED BY TRANSGENIC MCP-1 
PARASITE 
 
L. major MCP-1 cause lesions in CCR2 KO mice 
Previously it was demonstrated that transgenic MCP-1 parasites cause a healing 
phenotype in three different strains of mice including C57BL/6 mice.  We hypothesized 
that the parasite-derived MCP-1 was responsible for the healing phenotype in each of 
these strains of infected mice.  CCR2 KO mice lack the receptor for MCP-1.  Therefore, 
we were interested in repeating the in-vivo experiment with CCR2 KO mice.  If the 
parasite-derived MCP-1 was responsible for the healing phenotype than the phenotype 
should not be reproduced when CCR2 KO mice were infected with transgenic MCP-1 
secreting parasites because the MCP-1 would not have any CCR2 receptors to bind and 
signal.  Lesion progression was measured over a 51-day period.  Infection of CCR2 KO 
mice with either transgenic L. major MCP-1 (open squares) or wild-type parasites (closed 
squares) resulted in similar lesion progression (Figure 22A).  On day 51, wild-type 
parasites caused lesions of 1.95 + 0.18 mm, whereas transgenic parasites caused lesions 
of 1.75 + 0.11 mm.  The number of parasites on day 51 in the Lm-Tg infected CCR2 KO 
foot (4.16x105 + 1x105), lymph nodes (3475 + 664), and spleen (210 + 84) were 
comparable to the number of parasites in CCR2 KO mice infected with wild-type L. 
major parasites; foot (6.2x105 + 2x105), lymph nodes (4250 + 342), and spleen (425 + 53)  
(Figure 22B).  Parallel infection of C57BL/6 mice with transgenic parasites (open circles) 
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 Figure 22.  Lesion development in CCR2 KO mice.  CCR2 KO mice were 
similarly infected with Lm-WT (closed squares) or Lm-Tg (open squares) and 
compared to infections of Lm-Tg in C57BL/6 (open circles).  Parasite 
numbers were determined on day 51 for the CCR2 KO mice infected with 
Lm-WT (solid bars) and Lm-Tg (striped bars).  Error bars represent the 
standard error of the mean of two separate experiments done with a minimum 




parasites in the foot, lymph node, and spleen.  These observations suggest that the 
presence of CCR2, the receptor for MCP-1, on immune cells is required for the healing 
phenotype that we observe.   
Lack of adaptive immunity in mice infected with transgenic parasites 
We were interested in determining whether the healing phenotype caused by 
transgenic MCP-1 parasites was a result of adaptive or innate immunity.  Therefore, we 
infected RAG KO mice with the transgenic MCP-1 parasites to see if the healing 
phenotype was lost in RAG KO mice or whether the healing phenotype would be 
reproduced.  If the healing phenotype was lost in RAG KO mice, this would suggest that 
the phenotype is due to adaptive immunity.  If the healing phenotype was reproduced in 
RAG KO mice than it would suggest that only innate immunity is required.  RAG KO 
mice were infected with either 5x106 transgenic MCP-1 parasites or wild-type parasites.  
RAG KO mice infected with transgenic MCP-1 parasites developed no lesions with the 
mean peak swelling of 0.11 + 0.01 mm compared to RAG KO mice infected with wild-
type parasites that developed large lesions with a mean peak swelling of 4.36 + 0.37 mm 
(Figure 23A).  On day 35 post-infection, there were significantly higher numbers of 
parasites isolated from the foot (7.03x107 + 1.1x107), lymph node (4.87x106 + 1.4x106), 
and spleen (2188 + 442) from the RAG KO mice infected with Lm-WT compared to 
those isolated from mice infected with Lm-Tg; foot (88 + 18), lymph node (75 + 35), and 
spleen (0 + 0) (Figure 23B). 
We were interested in determining whether the avirulent transgenic MCP-1 
parasites could stimulate T-cell responses.  C57BL/6 mice were used in these studies 
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Figure 23.  Lack of lesion development in RAG KO mice.   
(A) RAG -/- mice on a C57BL/6 background were infected with 5x106 
Lm-WT (closed circles) or Lm-Tg (open circles) and lesion development 
was measured at weekly intervals.  (B)  Parasite burdens were quantitated 
on day 35 post-infection for RAG -/- mice infected with Lm-WT (solid 











immunological memory and protection against L. major105.  Lymphocytes isolated from 
the draining lymph nodes of mice infected with transgenic L. major MCP-1 on weeks 1, 
2, and 3 post-infection proliferated poorly in response to SLA stimulation (Figure 24, 
open bars), whereas mice infected with wild-type parasites exhibited strong proliferative 
responses (Figure 24, solid bars).  These SLA-stimulated lymphocytes from transgenic L. 
major MCP-1 infected mice secreted virtually no IFN-γ (Figure 25A, open bars) or IL-4 
(Figure 25B, open bars), whereas lymphocytes isolated from wild-type infected mice 
secreted significantly higher levels of IFN-γ (Figure 25A, solid bars) and IL-4 (Figure 
25B, solid bars).  There was essentially no spontaneous lymphocyte proliferation or 
cytokine production from either group in the absence of SLA stimulation (data not 
shown).  These data suggest that the adaptive immune response plays a minimal role in 
the clearance of transgenic MCP-1 parasites.   
This lack of adaptive immunity was confirmed in a vaccination study, in which 
C57BL/6 mice were infected in the right footpad with 5x104 transgenic L. major MCP-1 
or wild-type parasites.  After 5 weeks, when the lesions were resolving, these mice were 
challenged in the ear with 1x105 wild-type L. major parasites, as previously described.105  
As a control, an unprotected group was also challenged in the ear.  The ears were 
monitored over the course of the next 5 weeks for lesion development.  The unprotected 
group of mice developed progressive lesions as expected (Figure 26A, solid triangles), 
with substantial numbers of parasites in the ears (Figure 26B, striped bars) and lymph 
nodes (Figure 26C, striped bars).  Mice vaccinated with wild-type parasites were more 
resistant, developing healing lesions (Figure 26A, solid circles) with few detectable 





















Figure 24.  Lack of T-cell proliferation in mice 
infected with Lm-Tg.  C57BL/6 mice were infected 
with 5x104 Lm-WT or Lm-Tg parasites in the 
footpad.  Popliteal lymph nodes were isolated on 
weeks 1, 2, and 3 post-infection.  The proliferation of 
5x105 lymph node cells from mice infected with Lm-
WT (solid bars) or Lm-Tg (open bars) was measured 
by 3H-thymidine incorporation following stimulation 













































Figure 25.  Lack of cytokine production in mice infected 
with Lm-Tg.  (A) IFN-γ or (B) IL-4 was measured by ELISA 
following stimulation of lymph node T-cells from mice 
infected with Lm-WT (solid bars) or Lm-Tg (open bars).  
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Figure 26.  Transgenic MCP-1 parasites are unable to 
protect mice against secondary wild-type  Leishmania 
infection.  (A) C57BL/6 mice were vaccinated with 5x104 
viable Lm-WT or Lm-Tg parasites in the right footpad.  
Footpad lesions were monitored for 5 weeks.  After 5 
weeks, when lesions had resolved, 1x105 wild-type L. major 
parasites were injected into the ears of non-vaccinated 
(closed triangles), Lm-WT protected (closed circles), and 
Lm-Tg protected (open circles) C57BL/6 mice.  Ears were 
monitored over the next 5 weeks for lesion development.  
(B-C) Parasite burdens in the ears (B) and lymph node (C) 
were measured at 5 weeks.  Data are expressed as the mean 
+ SEM of three experiments with a minimum of five mice 




Mice vaccinated with transgenic L. major MCP-1, however, developed large lesions 
(Figure 26A, open circles) with high numbers of parasites in the ears (Figure 26B, open 
bars) and lymph nodes (Figure 26C,open bars).  By week 5, these lesions had begun to 
spread over the entire length of the ear and were necrotic (data not shown).  Thus, prior 
infection of mice with avirulent transgenic L. major MCP-1 parasites did not provide any 
protection against subsequent challenge with wild-type parasites and may even have 
inhibited the immune response to the ear challenge. 
The control of transgenic MCP-1 parasite infection coincides with increased migration of 
CCR2-positive macrophages 
We quantitated the migration of CCR2-positive (CD11b-positive, F4/80-positive, 
Gr-1-negative) macrophages into the ears of mice infected with transgenic L. major 
MCP-1 parasites during early stages of the infection.  BALB/c mice were infected in the 
ears with either transgenic L. major MCP-1 or wild-type parasites.  On various days post-
infection, cells were isolated from ears to identify cells migrating into the lesions.  At day 
7, there was a significant increase in the mean number of CCR2-positive macrophages 
(41,633 + 5994 [4.8% of total ear cells]) in the ears of mice infected with transgenic 
MCP-1 parasites (Figure 27A) compared to those infected with wild-type parasites  
(27,831 + 5799 [3.02% of total ear cells]) (Figure 27B).  This influx was transient and by 
day 14 the number of macrophages had begun to recede to levels similar to wild-type 
parasites.  There was no difference in the amount of cell migration between the two 
groups on day 21 post-infection (data not shown).  In addition, the number of neutrophils 
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Figure 27.  CCR2-positive macrophage migration into lesions.  BALB/c mice 
were infected with 5x104 (A) transgenic L. major MCP-1 or (B) wild-type L. major 
parasites.  Cells were isolated from infected ears on day 7 post-infection and labeled 
with antibodies to identify CD11b-positive, F4/80-positive, Gr-1-negative (data not 
shown) CCR2-positive macrophages by flow cytometry.  Percentages and cell 
numbers are based on the mean percentage of three separate experiments using the 
R1 gate.  Data are expressed as the mean + SEM of three experiments. 
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To determine the kinetics of disease resolution, we infected BALB/c mice in the ears 
with either wild-type or transgenic MCP-1 parasites.  The number of parasites in infected 
ears was quantitated at various times post-infection.  Significant differences in parasite 
loads between mice infected with either wild-type parasites or Lm-Tg began to 
appear as early as day 7 post-infection (Figure 28).  The number of parasites in the 
transgenic L. major MCP-1 infected ears decreased from 1292 + 84 on day 7 to only 467 
+ 9 on day 14.  In contrast, the number of wild-type parasites increased from 1.2x104 + 
2x103 on day 7 to 2.94x105 + 1.6x104 parasites on day 14 (Figure 28).  At this time, 
parasites began to disseminate into the lymph nodes of wild-type infected mice, but there 
was no dissemination into the lymph nodes in the Lm-Tg infected mice (data not shown). 
  To evaluate the level of macrophage infectivity in wild-type L. major and 
transgenic L. major MCP-1 infected BALB/c ears, total cells were isolated on days 7, 14, 
and 21 post-infection.  The cells were sorted to isolate a population of CD11b-positive, 
F4/80-positive, Gr-1-negative, CCR2-positive macrophages.  CCR2-positive 
macrophages isolated from Lm-Tg infected ears contained very few parasites and the low 
level of parasites remained relatively constant over the entire observation period (Figure 
29A).  By day 21, CCR2-positive macrophages from Lm-Tg infected ears contained few 
or no intact parasites (Figure 29B).  However, macrophages isolated from wild-type L. 
major infected ears contained high numbers of parasites per 100 macrophages and this 
number progressively increased over time (Figure 29A).  By day 21, the CCR2-positive 
macrophages from wild-type infected ears were heavily infected with high numbers of 
































 Figure 28.  Reduced parasite loads in Lm-Tg infected BALB/c 
mice by day 7 post-infection.  BALB/c mice were infected with 
5x104 Lm-WT (closed circles) or Lm-Tg parasites (open circles) in 
the ear.  Parasite burdens in infected ears were enumerated at 2 
hours and at days 3, 7, 14, and 21 post-infection.  The experiment 
was repeated three times using a minimum of 5 mice per group. (*, 





































Figure 29.  Low infectivity of transgenic infected 
CCR2-positive macrophages.  (A) Total cells were 
isolated from infected ears on day 7, 14, and 21 post-
infection, and CD11b-positive, F4/80-positive, Gr-1-
negative, CCR2-positive macrophages were sorted.  
The number of parasites per 100 CCR2-positive 
macrophages isolated from Lm-WT (solid bars) or 
Lm-Tg (open bars) infected mice was compared.  (B-
C) Sorted CCR2-positive macrophages were 
cytospun and Giemsa stained to examine macrophage 
infectivity.  Macrophages from day 21 ears infected 





The kinetics of disease resolution and the levels of CCR2-positive macrophage 
infectivity were analyzed in wild-type and Lm-Tg infected C57BL/6 ears as well as 
CCR2 KO ears.  Similar to the observations in BALB/c mice, there were significantly  
fewer Lm-Tg parasites in the ears of C57BL/6 mice by as early as day 7 (Figure 30A).  
On day 21, the CCR2-positive macrophages from wild-type infected C57BL/6 ears were 
heavily infected with parasites (Figure 30B), whereas those from Lm-Tg infected mice 
were not (Figure 30C). 
In contrast to the C57BL/6 mice, infection of CCR2 KO mice with either wild-
type or transgenic MCP-1 parasites resulted in the increased parasite accumulation in the 
ears over the 21 day observation period (Figure 31A).  At this time, macrophages from 
the infected CCR2 KO mice contained high levels of wild-type (Figure 31B) or 
transgenic MCP-1 (Figure 31C) parasites in them.  These data further confirms that a 
population of CCR2-positive macrophages is migrating toward the parasite-derived 
MCP-1 and plays a role in eradicating the parasites. 
 
Recruited CCR2-positive macrophages and MCP-1 co-activation 
 
 To determine how recruited CCR2-positive macrophages were capable of killing 
intracellular parasites, mice were injected i.p. with recombinant MCP-1 to recruit 
restrictive CCR2-positive macrophages to the peritoneum.  These cells were isolated and 
stimulated in-vitro under various conditions.  Intracellular killing of wild-type parasites 
was enhanced when MCP-1 recruited macrophages were activated with both MCP-1 and 
IFN-γ in-vitro (Table 3).  Optimal parasite killing appeared to require both recruitment of 
CCR2-positive macrophages and stimulation of these cells since the removal of either 


































  Figure 30.  Reduced parasite loads in Lm-
Tg infected C57BL/6 mice by day 7 post-
infection.  (A) Parasite numbers in the ears 
of C57BL/6 mice were determined at 
weekly intervals following infection with 
5x104 Lm-WT (closed circles) or Lm-Tg 
parasites (open circles).  (B-C) Intracellular 
parasites within sorted CCR2-positive 
macrophages isolated from the ears of 
C57BL/6 mice, 21 days after infection with 







































Figure 31.  Parasite levels in the infected ears of 
CCR2 KO mice.  Parasite numbers in the ears of 
CCR2 KO mice were determined at various time 
points following infection with 5x104 Lm-WT 
(closed circles) or Lm-Tg (open circles) parasites.  
(B-C) Intracellular parasites within macrophages 
isolated from the ears of CCR2 KO mice, 21 days 












TABLE 3.   Killing of wild-type Leishmania by MCP-1 recruited macrophages 
 
 












 85a ± 3b 
 
248 ± 10 
 
38 ± 4 
 




       84 ± 4 
 
  238 ± 22 
 









84 ± 3 
 
249 ± 6 
 
32 ± 2 
 
No stimulation 100 
 
81 ± 3  232 ± 18 34 ± 3 
 
IFN-γ (100 U) 100 
 
84 ± 3 
 
235 ± 16 
  
    33 ± 5 
 
 
MCP-1 (1 ng) 100 
 
87 ± 2 
 
      219 ± 8 
 








IFN-γ (100 U) + MCP-1 (1 ng) 100   72 ± 4 *    159 ± 15 ** 
 
      19 ± 2 ** 
  
 
a    Mean number counted in three different coverslips 
b    Standard deviation 
c    Macrophages were infected with wild-type L. major parasites 
*    Significantly different when compared to either non-stimulated, IFN-γ or MCP-1 stimulated samples (p < 0.05) 











stimulating them with two signals: a TLR agonist and IFN-γ.  Classically activated 
macrophages make pro-inflammatory cytokines and NO, which allow them to kill 
intracellular pathogens such as Leishmania.  CCR2-positive macrophages are similar in 
the sense that they also require two signals.  After migrating to the site of infection, these 
CCR2-positive macrophages appear to require both MCP-1 and IFN-γ to enhance parasite 
killing.  This suggests that transgenic parasites expressing MCP-1 both recruit and 





Mice lacking the CCR2 receptor on the C57BL/6 background developed 
relatively normal lesions when infected with Lm-Tg parasites.  This suggests that  
signaling through the CCR2 receptor was required for the healing phenotype.  In all of 
these strains, the phenotype caused by transgenic MCP-1 parasites was very dramatic.  
While the wild-type parasites caused large lesions with many parasites, the transgenic L. 
major MCP-1 parasites failed to cause measurable lesions and the number of parasites in 
the lesions and visceral organs was dramatically reduced.   
Several experiments were performed to discover whether the CCR2-positive cells 
that caused the healing phenotype were part of the innate or adaptive immune response 
that develops in mice infected with transgenic MCP-1 parasites.  We first observed that 
mice lacking a functional adaptive immune response (RAG KO mice) when infected with 
Lm-Tg developed the healing phenotype.  The reproducible healing phenotype in RAG 
KO mice showed that lymphocytes were not required for the healing phenotype observed 
in mice previously infected with Lm-Tg.  This also suggested that the immune cells 
responsible for the healing phenotype were part of innate immunity.  Next, we observed 
that lymph node-derived lymphocytes obtained from mice infected with transgenic MCP-
1 parasites were not able to proliferate or secrete  IFN-γ or IL-4 in response to soluble 
Leishmania antigen, in contrast to lymphocytes from wild-type infected mice.  The lack 
of T-cell proliferation and cytokine production suggested that the transgenic MCP-1 
parasites were cleared by an innate immune response before an adaptive immune 
response was generated.  The role of innate immunity in the healing phenotype caused by 
Lm-Tg  was verified by a follow-up vaccination experiment.  Mice that were infected in 
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the footpad with transgenic MCP-1 parasites were not protected 5 weeks later when re-
infected in the ear with wild-type parasites.  However, mice previously infected with 
wild-type parasites in the footpad were completely protected when similarly challenged.  
These results are consistent with the idea that mice infected with transgenic MCP-1 
parasites did not develop a detectable adaptive immune response.  We therefore decided 
to focus on the innate immune response in mice infected with transgenic MCP-1 
parasites.  In an attempt to identify the early events that could be responsible for these 
lesion differences, we focused on the cells migrating into infected ears during the first 
week.  On day 7 post-infection, there was a 50% increase in the number of CCR2-
positive macrophages migrating into the transgenic MCP-1 infected ears relative to the 
wild-type infected ears.  The increased CCR2-positive macrophage migration correlated 
with significant differences in parasite levels between wild-type and Lm-Tg infected ear 
lesions in both BALB/c and C57BL/6 mice.  These differences in parasite numbers were 
detected as early as 7 days post-infection and they continued to increase over time.  The 
CCR2-positive macrophages that were sorted on days 7, 14, and 21 post-infection from 
Lm-Tg infected BALB/c and C57BL/6 ears contained few if any parasites, whereas 
CCR2-positive macrophages from wild-type infected ears were heavily infected.  In 
contrast, there were no differences in parasite levels in macrophages from infected CCR2 
KO mice.  These data suggests that transgenic L. major MCP-1 may recruit a population 
of CCR2-positive macrophages that prevent intracellular parasite growth and survival. 
One potential scenario that could account for the lack of lesion formation in Lm-
Tg infected mice is that macrophages may become activated by MCP-1, leading to 
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parasite killing.  This would be consistent with previous in vitro observations of others85-
89.   
A second possibility is that a specific CCR2-positive macrophage subset may be 
recruited into the lesion and this subset may be particularly adept at killing intracellular 
organisms.  Recently, a CCR2-positive monocyte population has been identified that 
migrates into inflammatory sites and is believed to play a role in pathogen clearance5;106.  
In addition, a CCR2-positive Gr-1-positive macrophage population was shown to control 
toxoplasmosis6;7.  This population, like our restrictive CCR2-positive macrophage 
population, expresses CCR2 and controls parasite dissemination.  However, the 
population was also reported to express Gr-1, a marker that we did not detect on our 
CCR2-positive macrophages.   
Our in-vitro MCP-1 activation studies using MCP-1 recruited macrophages 
(Table 3) suggests that both scenarios may be true.  We suggest that the transgenic MCP-
1 secreting parasites recruit restrictive CCR2-positive macrophages to the site of 
infection.  The MCP-1 produced by the transgenic parasites also helps to activate the 
CCR2-positive macrophages making them particularly adept at killing Leishmania 
parasites. 
Others have shown that CCR2 KO mice on a C57BL/6 background infected with 
L. major developed larger ear lesions with higher numbers of parasites compared to 
infected CCR2 +/+ C57BL/6 mice82.  This increased disease severity in infected CCR2 
KO mice was attributed to a lack of Langerhans cell (LCs) migration from the ear to the 
lymph node, thereby affecting antigen presentation to T-cells.  Others have questioned 
the role of LCs in antigen presentation during leishmaniasis107.  Although we 
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acknowledge that the lack of DC migration (whether LCs or dermal DCs) contributes to 
increased lesion progression in wild-type L. major infected CCR2 KO, we would 
speculate that the increased disease severity could also be attributed to a lack of 
recruitment of the CCR2-positive macrophages into the infected ear late in the infection.   
Previously, it has been shown that L. major induces MCP-1 production in lymph 
nodes of C3H mice resistant to L. major, but does not induce MCP-1 in BALB/c mice 
susceptible to L. major108.  In addition, MCP-1 and CCR2 mRNA were detected in the 
footpads of resistant C57BL/6 mice infected with L. major between 2-4 weeks post-
infection109.  Based on our findings with the MCP-1 transgenic parasites, it is possible 
that the MCP-1 produced in resistant mouse strains is the main chemoattractant recruiting 
a restrictive CCR2-positive macrophage subset to the localized site of infection.  These 
macrophages may assist in resolving the lesions when co-activated with MCP-1, while 
the lack of MCP-1 production may prevent any such CCR2-positive macrophage 
recruitment from ever occurring in susceptible BALB/c mice.  A similar idea can be used 
to explain the events that lead to self-healing cutaneous leishmaniasis in humans, as other 
groups have already discovered the presence of MCP-1 in self-healing cutaneous lesions 
and the absence of MCP-1 in the non-healing diffuse cutaneous leishmaniasis75-77.  The 
MCP-1 present in self-healing lesions may recruit and co-activate restrictive CCR2-
positive macrophages to the site of infection to kill the parasites and resolve the lesions.  
Future studies will attempt to identify subpopulations of CCR2-positive 
macrophages and biochemically define the macrophage subset recruited by the parasite-
derived MCP-1 that is important for early parasite control during leishmaniasis. 
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Overall, we feel that the transgenic MCP-1 secreting parasites are infecting 
macrophages and producing MCP-1 intracellularly.  The parasite-derived MCP-1 
accumulates within the infected macrophages until the cell bursts due to parasite 
replication, releasing transgenic MCP-1 amastigotes and also parasite-derived MCP-1.  
The parasite-derived MCP-1 recruits restrictive CCR2-positive macrophages to the site of 
infection and these macrophages are optimally activated with MCP-1 and IFN-γ making 
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